Granahan Investment Management’s BridgeBio Pharma BBIO Stock Holding History

Granahan Investment Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.38M	Sell	99,130 -3,781	-4%	-$265K	0.26%	90
2026 Q1	$7.64M	Buy	102,911 +1,106	+1%	+$80.2K	0.37%	67
2025 Q4	$7.79M	Sell	101,805 -59,473	-37%	-$3.9M	0.33%	72
2025 Q3	$8.38M	Buy	161,278 +78,588	+95%	+$3.83M	0.34%	71
2025 Q2	$3.57M	Buy	+82,690	New	+$3.01M	0.15%	116
2024 Q4	–	Sell	-183,788	Closed	-$4.68M	–	182
2024 Q3	$4.68M	Sell	183,788 -67,737	-27%	-$1.78M	0.18%	134
2024 Q2	$6.37M	Sell	251,525 -205,461	-45%	-$5.62M	0.25%	107
2024 Q1	$14.1M	Buy	456,986 +68,684	+18%	+$2.34M	0.5%	64
2023 Q4	$15.7M	Buy	388,302 +279,481	+257%	+$8.39M	0.52%	61
2023 Q3	$2.87M	Buy	+108,821	New	+$3.09M	0.1%	150

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Granahan Investment Management's BBIO Position: Q2 2026 in Review

Granahan Investment Management reduced its BridgeBio Pharma (BBIO) stake by 3.7% in Q2 2026, selling an estimated $265K and leaving 99,130 shares worth $7.38M. The position accounts for 0.26% of the portfolio, ranked #90.

Granahan Investment Management first reported a position in BBIO in Q3 2023 and has held it in 10 quarters since. The position peaked at $15.7M in Q4 2023. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Granahan Investment Management held 99,130 shares of BridgeBio Pharma worth $7.38M as of Q2 2026.
Granahan Investment Management sold 3,781 BridgeBio Pharma shares in Q2 2026, an estimated $265K.
BridgeBio Pharma made up 0.26% of Granahan Investment Management's portfolio in Q2 2026, its #90 holding.
Granahan Investment Management first reported a position in BridgeBio Pharma in Q3 2023 and has held it in 10 quarters since.
Granahan Investment Management's BridgeBio Pharma position peaked at $15.7M in Q4 2023.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Granahan Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.